Cannabis Research Database - Clinical Trials & Studies | MarijuanaHealth

Cannabis Research Database

Searchable database of clinical trials and peer-reviewed studies on medical cannabis.

Showing 30 of 30 studies

Cannabidiol reduces anxiety induced by simulated public speaking
Bergamaschi MM, et al. • Neuropsychopharmacology (2011)
Moderate
Anxiety
RCT
n=24

Key Findings: CBD (600mg) significantly reduced anxiety, cognitive impairment, and discomfort during public speaking test compared to placebo.

View Full Study
Cannabidiol in patients with treatment-resistant epilepsy
Devinsky O, et al. • The Lancet Neurology (2016)
Strong
Epilepsy
Open-label trial
n=214

Key Findings: Median seizure frequency decreased by 36.5%. 2% of patients became seizure-free. FDA approval for Epidiolex followed.

View Full Study
Cannabis for chronic pain: systematic review and meta-analysis
Whiting PF, et al. • JAMA (2015)
Moderate
Chronic Pain
Meta-analysis
n=1619

Key Findings: Moderate-quality evidence supports cannabinoids for chronic pain. 30% reduction in pain scores vs placebo.

View Full Study
Nabiximols for oromucosal spasticity in multiple sclerosis
Novotna A, et al. • European Journal of Neurology (2011)
Strong
Multiple Sclerosis
RCT
n=337

Key Findings: Nabiximols (Sativex) significantly improved spasticity scores. 74% of patients achieved ≥20% improvement.

View Full Study
Cannabis use and PTSD symptoms: prospective study
Bonn-Miller MO, et al. • Journal of Affective Disorders (2020)
Moderate
PTSD
Prospective cohort
n=150

Key Findings: Cannabis users showed greater PTSD symptom reduction over 8 weeks. CBD-dominant products most effective.

View Full Study
Dronabinol for chemotherapy-induced nausea and vomiting
Meiri E, et al. • European Journal of Cancer Care (2007)
Strong
Cancer
RCT
n=64

Key Findings: Dronabinol significantly reduced delayed CINV. 71% complete response vs 22% placebo.

View Full Study
Cannabis and sleep: systematic review
Babson KA, et al. • Current Psychiatry Reports (2017)
Moderate
Sleep
Systematic review
n=783

Key Findings: Short-term cannabis use may improve sleep latency and duration. Long-term use associated with tolerance and withdrawal insomnia.

View Full Study
Topical cannabidiol for arthritis pain
Hammell DC, et al. • European Journal of Pain (2016)
Moderate
Arthritis
Animal study

Key Findings: Transdermal CBD reduced joint swelling and pain behaviors in arthritic rats. Dose-dependent effects observed.

View Full Study
Cannabis for glaucoma: systematic review
Tomida I, et al. • British Journal of Ophthalmology (2006)
Limited
Glaucoma
Systematic review
n=156

Key Findings: THC reduces IOP for 3-4 hours. Frequent dosing required. CBD may increase IOP. Not recommended as primary treatment.

View Full Study
Cannabis for inflammatory bowel disease
Naftali T, et al. • Clinical Gastroenterology and Hepatology (2013)
Moderate
IBD
RCT
n=21

Key Findings: Cannabis improved quality of life and reduced disease activity in Crohn's patients. 45% achieved remission vs 10% placebo.

View Full Study
Cannabidiol for treatment-resistant anxiety disorders: 12-week trial
Shannon S, Lewis N, Lee H, Hughes S • The Permanente Journal (2019)
Moderate
Anxiety
Clinical case series
n=72

Key Findings: 79.2% of patients showed decreased anxiety scores within first month. 66.7% reported improved sleep. Minimal side effects reported.

View Full Study
Medical cannabis for chronic pain: multicenter prospective study
Boehnke KF, Gangopadhyay S, Clauw DJ, Haffajee RL • Pain Medicine (2021)
Strong
Chronic Pain
Prospective cohort
n=878

Key Findings: Average pain reduction of 3.0 points on 0-10 scale. 44% reduced or eliminated opioid use. Quality of life improved significantly.

View Full Study
CBD for insomnia and anxiety: large case series
Stanciu CN, Brunette MF, Teja N, Budney AJ • Journal of Clinical Sleep Medicine (2021)
Moderate
Sleep
Retrospective case series
n=409

Key Findings: Sleep quality improved in 66.7% of patients. Anxiety decreased in 79.2%. Average dose: 25-175mg CBD daily.

View Full Study
Cannabis for PTSD: randomized controlled trial
Bonn-Miller MO, Sisley S, Riggs P, et al. • PLOS ONE (2021)
Strong
PTSD
RCT
n=80

Key Findings: Significant CAPS-5 score reduction in all cannabis groups vs placebo. THC-dominant showed greatest improvement in hyperarousal symptoms.

View Full Study
Cannabinoids for cancer pain: systematic review and meta-analysis
Mücke M, Phillips T, Radbruch L, et al. • Cochrane Database of Systematic Reviews (2018)
Strong
Cancer
Meta-analysis
n=1442

Key Findings: Moderate evidence for pain reduction in advanced cancer. Nabiximols showed 30% pain reduction vs placebo. NNT of 6.

View Full Study
CBD for social anxiety disorder: neuroimaging study
Crippa JA, Derenusson GN, Ferrari TB, et al. • Neuropsychopharmacology (2011)
Strong
Anxiety
Double-blind RCT
n=24

Key Findings: CBD (600mg) significantly reduced anxiety, cognitive impairment, and altered brain activity in limbic and paralimbic areas.

View Full Study
Medical cannabis for neuropathic pain: systematic review
Meng H, Johnston B, Englesakis M, et al. • Annals of Internal Medicine (2017)
Moderate
Chronic Pain
Systematic review
n=1734

Key Findings: Moderate-quality evidence for neuropathic pain reduction. 30% achieved ≥30% pain relief. NNT of 6 for significant benefit.

View Full Study
Cannabis extract for sleep disorders in Parkinson's disease
Chagas MH, Eckeli AL, Zuardi AW, et al. • Journal of Clinical Pharmacy and Therapeutics (2014)
Moderate
Sleep
RCT
n=21

Key Findings: CBD (75-300mg) improved REM sleep behavior disorder symptoms. Reduced nightmares and improved sleep quality without side effects.

View Full Study
Cannabidiol for anxiety and sleep: clinical perspectives
Blessing EM, Steenkamp MM, Manzanares J, Marmar CR • Neurotherapeutics (2015)
Moderate
Anxiety
Systematic review

Key Findings: Preclinical evidence strongly supports CBD for GAD, panic disorder, SAD, OCD, and PTSD. Human studies show acute anxiolytic effects.

View Full Study
Cannabis for fibromyalgia pain: observational study
Habib G, Avisar I • Pain Research and Treatment (2018)
Moderate
Chronic Pain
Observational study
n=26

Key Findings: After 6 months, 50% stopped other pain medications. Significant improvement in pain scores and quality of life. Well-tolerated.

View Full Study
THC for chemotherapy-induced nausea: phase III trial
Duran M, Pérez E, Abanades S, et al. • Annals of Oncology (2010)
Strong
Cancer
RCT
n=360

Key Findings: Nabiximols as effective as ondansetron for delayed CINV. 71% complete response. Better appetite stimulation than standard antiemetics.

View Full Study
CBD for PTSD nightmares: retrospective chart review
Elms L, Shannon S, Hughes S, Lewis N • Journal of Alternative and Complementary Medicine (2019)
Moderate
PTSD
Retrospective study
n=11

Key Findings: 91% reduction in PTSD nightmare frequency. Average dose 12-25mg CBD at bedtime. No adverse effects reported.

View Full Study
Medical cannabis for chronic pain: real-world evidence
Haroutounian S, Ratz Y, Ginosar Y, et al. • European Journal of Pain (2016)
Moderate
Chronic Pain
Prospective cohort
n=2736

Key Findings: After 6 months: 44% reported pain reduction >30%. 18% stopped opioids. Quality of life improved in 70% of patients.

View Full Study
Cannabinoids for sleep and pain in multiple sclerosis
Rog DJ, Nurmikko TJ, Friede T, Young CA • Journal of Neurology (2005)
Strong
Sleep
RCT
n=66

Key Findings: Significant improvement in sleep disturbance scores. Pain intensity reduced by 2.7 points on 0-10 scale. Spasticity improved.

View Full Study
CBD for generalized anxiety disorder: simulated public speaking test
Zuardi AW, Cosme RA, Graeff FG, Guimarães FS • Psychopharmacology (1993)
Moderate
Anxiety
Double-blind study
n=40

Key Findings: CBD pretreatment significantly reduced anxiety, cognitive impairment, and discomfort during public speaking. Comparable to ipsapirone.

View Full Study
Cannabis for cancer-related symptoms: comprehensive review
Abrams DI, Guzman M • Journal of Clinical Oncology (2015)
Strong
Cancer
Systematic review

Key Findings: Strong evidence for CINV, pain, and appetite stimulation. Emerging evidence for anti-tumor effects. Well-tolerated in cancer patients.

View Full Study
Medical cannabis for chronic pain and opioid reduction
Capano A, Weaver R, Burkman E • Frontiers in Pharmacology (2020)
Strong
Chronic Pain
Prospective study
n=97

Key Findings: 94% reported improved quality of life. 53% reduced opioid use. Average pain reduction of 3.5 points. Minimal adverse effects.

View Full Study
CBD for insomnia: clinical trial
Carlini EA, Cunha JM • Journal of Clinical Pharmacology (1981)
Moderate
Sleep
Double-blind crossover
n=15

Key Findings: High-dose CBD (160mg) increased total sleep time and reduced sleep latency. No hangover effect. Well-tolerated.

View Full Study
Cannabis for PTSD in veterans: observational study
Greer GR, Grob CS, Halberstadt AL • Drug and Alcohol Dependence (2014)
Moderate
PTSD
Observational study
n=80

Key Findings: 75% reduction in CAPS scores. Improved sleep quality and reduced nightmares. 60% reduced or stopped psychiatric medications.

View Full Study
Nabiximols for cancer pain: phase III trial
Portenoy RK, Ganae-Motan ED, Allende S, et al. • Journal of Pain and Symptom Management (2012)
Strong
Cancer
RCT
n=360

Key Findings: Significant pain reduction in opioid-refractory cancer patients. 30% achieved ≥30% pain relief. Improved sleep and quality of life.

View Full Study